A PATIENT IN THE LAB^®

HUB Organoids predict patient response to treatment.

Our patented technology allows the development of patient-derived “mini-organs in a dish” from both healthy and diseased tissues to close the gap between the lab and the clinic.

LATEST BLOG!

Regulators Embrace Organoids: Inside the FDA’s Shift Away from Animal Model

What we can do for you

Drug development

Reduce drug attrition and predict patient response with our preclinical services and clinical trials in a dish
Link

Custom solutions

Decipher the complexity of the human disease with our custom model and assay development services
Link

License HUB Organoid Technology

Licensing program

Bring HUB Organoid Technology and knowhow in-house
Link

Our therapeutic areas

Oncology

Immuno-oncology

Inflammatory diseases

Genetic
diseases

Infectious diseases

Toxicology

We’re already making an impact

by bringing next-generation therapeutics to patients

Bring HUB Organoid Technology and knowhow in-house

Outsource your drug development program

Latest news

NEWS & PRESS RELEASE

HUB Organoids B.V. Awarded Frost & Sullivan’s 2024 Technology Innovation Leadership Award for Transforming Drug Development with Highly Advanced Organoid Technology

NEWS

The Life Science business of Merck KGaA, Darmstadt, Germany Acquires HUB Organoids Holding B.V., Expands Next-Gen Biology Portfolio

BLOG

A beginner’s guide to Inflammatory Bowel Diseases (IBD)